[go: up one dir, main page]

UY28630A1 - Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol - Google Patents

Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol

Info

Publication number
UY28630A1
UY28630A1 UY28630A UY28630A UY28630A1 UY 28630 A1 UY28630 A1 UY 28630A1 UY 28630 A UY28630 A UY 28630A UY 28630 A UY28630 A UY 28630A UY 28630 A1 UY28630 A1 UY 28630A1
Authority
UY
Uruguay
Prior art keywords
beta
estra
diol
trien
vinil
Prior art date
Application number
UY28630A
Other languages
English (en)
Inventor
Olaf Peters
Karl-Heinrich Fritzemeier
Christa Hegele-Hartung
Ludwing Neyses
Theo Pelzer
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of UY28630A1 publication Critical patent/UY28630A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Uso de los agonistas de ERB(beta) 8B(beta)-vinil-estra-1,3,5(10)-trien-3,17B(beta)-diol y 17B(beta)-fluor.9a-vinil-estra-1,3,5(10)-tien -3 16a-diol para producir medicamentos para la prevención y/o el tratamiento de enfermedades cardíacas hipertensivas, especialmente para la prevención y/o el tratamiento de una o más de las condiciones seleccionadas del grupo que consiste en (1) hipertensión, (2) hipertrofia cardiaca y (3) deficiencia cardíaca.
UY28630A 2003-11-26 2004-11-23 Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol UY28630A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03090406 2003-11-26

Publications (1)

Publication Number Publication Date
UY28630A1 true UY28630A1 (es) 2005-06-30

Family

ID=34626396

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28630A UY28630A1 (es) 2003-11-26 2004-11-23 Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol

Country Status (16)

Country Link
US (1) US20050148560A1 (es)
EP (1) EP1689410B1 (es)
JP (1) JP2007512279A (es)
AR (1) AR046672A1 (es)
AT (1) ATE395919T1 (es)
DE (1) DE602004014020D1 (es)
DK (1) DK1689410T3 (es)
ES (1) ES2307064T3 (es)
GT (1) GT200400241A (es)
PA (1) PA8618401A1 (es)
PE (1) PE20050665A1 (es)
PL (1) PL1689410T3 (es)
PT (1) PT1689410E (es)
TW (1) TW200530263A (es)
UY (1) UY28630A1 (es)
WO (1) WO2005051401A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
TWI392682B (zh) * 2006-04-13 2013-04-11 Sigma Tau Ind Farmaceuti 作為心血管疾病的治療藥物之雄甾烷和雄甾烯的胺基衍生物
TWI389917B (zh) * 2006-04-13 2013-03-21 Sigma Tau Ind Farmaceuti 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物
BRPI0806371A2 (pt) 2007-01-22 2011-09-13 Gtx Inc agentes ligação de receptor nuclear
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
US20110152840A1 (en) * 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
WO2017059070A1 (en) 2015-09-29 2017-04-06 Amag Pharmaceuticals, Inc. Crystalline and amorphous form of 17-a- hydroxyprogesterone caproate

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2245694T3 (es) * 2000-04-12 2006-01-16 Schering Aktiengesellschaft Derivados de 11beta-pentil- y 11beta-hexil-estra-1,3,5(10)-trienos sustituidos en la posicion 8beta.
DE10019167A1 (de) * 2000-04-12 2001-10-18 Schering Ag Substituierte Estratriene als selektiv wirksame Estrogene
GB2374412A (en) * 2001-04-11 2002-10-16 Karobio Ab Hypertension treatment and assay
US7414043B2 (en) * 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
DE10226326A1 (de) * 2002-06-11 2004-01-15 Schering Ag 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Also Published As

Publication number Publication date
GT200400241A (es) 2005-10-31
DK1689410T3 (da) 2008-09-08
DE602004014020D1 (de) 2008-07-03
PA8618401A1 (es) 2005-08-04
US20050148560A1 (en) 2005-07-07
EP1689410A2 (en) 2006-08-16
ATE395919T1 (de) 2008-06-15
TW200530263A (en) 2005-09-16
PL1689410T3 (pl) 2008-10-31
JP2007512279A (ja) 2007-05-17
EP1689410B1 (en) 2008-05-21
PE20050665A1 (es) 2005-11-02
WO2005051401A3 (en) 2005-09-01
AR046672A1 (es) 2005-12-14
WO2005051401A2 (en) 2005-06-09
PT1689410E (pt) 2008-08-18
ES2307064T3 (es) 2008-11-16

Similar Documents

Publication Publication Date Title
ES2571588T3 (es) Válvula cardiaca sustituible
CY1115117T1 (el) Παραγωγα υποκατεστημενων οξαζολιδινονων και η χρηση τους ως αναστολεις παραγοντα χα
ECSP045382A (es) Fenilacetamidas sustituidas y su uso como activadores de glucoquinasa
ECSP066411A (es) Tienopirazoles
UY28630A1 (es) Prevención y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de lso estrógenos selectivos 8b(beta) -vinil-estra-1,3,5 (10)-trien-3, 17b(beta)-diol y 17b(beta) -fluor-9a(alfa)-vinil-estra-1,3,6(10)-trien-3,16a(alfa)-diol
UY29504A1 (es) Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
NO20074412L (no) Bruddresistente administrasjonsformer med forsinket frigiving
AR037109A1 (es) Uso de flibanserina
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
ES2191286T3 (es) Moleculas pequeñas, utiles en el tratamiento de enfermedades inflamatorias.
HN1999000124A (es) Derivados de pirazol substituido.
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
AR029837A1 (es) Anilidas de acidos sulfonicos substituidas
ATE359279T1 (de) Moschus-geruchsstoffe
UY28253A1 (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparación, medicamentos que comprenden este compuesto y su uso.
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
CY1106092T1 (el) Χρηση του μακρου μοριου της πεντραξινης ρτχ3 για τη θepαπεια ασθενειων που προκαλουνται απο μια μεταβαλλομενη ενepγοποιηση του αυξητικου παραγοντα fgf-2
BR0307903A (pt) derivados de arilsulfona
SV2003000607A (es) Composiciones y metodos para la deteccion de biomarcadores relacionados con la enfermedad cardiovascular
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
HRP20050439B1 (en) New use of dextran sulfate
UY27451A1 (es) 2,5-diamidoindoles sustituidos y su utilización
ITRM20030194A0 (it) Uso di derivati del 7-nitro-2,1,3-benzossadiazolo per la terapia di forme tumorali.
NO20062384L (no) Anvendelse av BH4 for bahandling av respiratoriske sykdommer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150525